A Republican bill with 3 Democratic cosponsors · See all 4 cosponsors
Last activity — Referred to the House Committee on Ways and Means.
In committee
Introduced and handed to a committee in the chamber it started in.
The committee holds it, and most bills are never heard from again. A hearing or a committee vote would be news; silence is the usual outcome, and it kills the bill without anyone voting against it.
Its path through Congress
- Introduced
- In Committee
What this bill would do
This bill, called the "No Handouts for Drug Advertisements Act," aims to amend the Internal Revenue Code of 1986 to disallow tax deductions for advertising and promotional expenses related to direct-to-consumer advertising of certain prescription drugs. This would affect sponsors of prescription drugs and owners of outsourcing facilities. The changes would apply to expenses paid after the bill's enactment.
Yes· 3 of 7
- Scored +2
Does this raise the taxes companies pay?
By disallowing tax deductions for drug advertising, it effectively increases the tax burden on pharmaceutical companies.
- Scored +2
Does this lower the price of prescription medicines?
By disallowing advertising deductions, the bill might encourage drug companies to reduce prices.
- Scored +1
Does this reduce what the federal government owes?
The bill could lead to a slight reduction in the national debt by increasing government revenue through reduced tax deductions.
The opposite
- Scored -1
Would business owners be better off under this?
Pharmaceutical company owners may see a negative impact due to reduced tax deductions.
Who it would affect, and how
Potential Positive Impacts for People
- The bill denies deductions for direct-to-consumer advertising expenses for certain drugs (Sec. 2). This might lead to lower drug prices if pharmaceutical companies reduce advertising spending and pass those savings on to consumers.
Potential Negative Impacts for People
- Denying deductions for advertising (Sec. 2) could cause drug companies to reduce their marketing efforts, which could limit the information available to patients about new or existing drugs, potentially affecting healthcare decisions.
Groups and Interests Ranking
Every group the model scored this bill for, from -10 to +10. Tap or hover a score for the reason it gave.
- Economy And Finance
- Does this raise the taxes companies pay? — By disallowing tax deductions for drug advertising, it effectively increases the tax burden on pharmaceutical companies. Does this make the government pay for what it commits to? — The bill promotes fiscal responsibility by limiting tax deductions for specific expenditures. Does this reduce what the federal government owes? — The bill could lead to a slight reduction in the national debt by increasing government revenue through reduced tax deductions.
- Healthcare
- Does this lower the price of prescription medicines? — By disallowing advertising deductions, the bill might encourage drug companies to reduce prices. Does this lower what people pay for private health insurance? — If drug companies pass savings from reduced advertising costs to consumers, it could potentially lower insurance premiums.
- Demographic And Interest Groups
- Would households on low incomes be better off under this? — Potentially lower drug costs or insurance premiums could benefit low-income households. Would middle-income households be better off under this? — Potentially lower drug costs or insurance premiums could benefit middle-class households. Would business owners be better off under this? — Pharmaceutical company owners may see a negative impact due to reduced tax deductions.
- 10/21/2025
- 1 Cosponsor added.
- 4/24/2025
- Referred to the House Committee on Ways and Means.
- 3 Cosponsors added.
- Introduced in House
One bill Congress.gov lists as related to this one — companions in the other chamber, earlier versions, and bills this one absorbed or was folded into.
Nicholas BegichRepublican · Alaska
Angie CraigDemocrat · Minnesota
Hillary ScholtenDemocrat · Michigan
Eugene VindmanDemocrat · Virginia